Provided by Tiger Trade Technology Pte. Ltd.

Halozyme Therapeutics

107.72
+1.231.16%
Post-market: 107.720.00000.00%19:47 EDT
Volume:1.06M
Turnover:113.76M
Market Cap:12.23B
PE:31.85
High:108.53
Open:107.45
Low:106.87
Close:106.49
52wk High:109.66
52wk Low:61.23
Shares:113.50M
Float Shares:112.00M
Volume Ratio:0.69
T/O Rate:0.95%
Dividend:- -
Dividend Rate:- -
EPS(TTM):3.38
EPS(LYR):2.56
ROE:173.67%
ROA:25.49%
PB:85.17
PE(LYR):42.08

Loading ...

Barfresh Food Names CEO Delle Coste Interim CFO as Lisa Roger Retires

Reuters
·
9 hours ago

Is Halozyme Therapeutics (HALO) Overvalued After Its New Board Appointment?

Simply Wall St.
·
Aug 29

Halozyme Director Dannielle Appelhans Files Initial Beneficial Ownership Statement

Reuters
·
Aug 22

Halozyme CEO Helen Torley Sells USD 4.13 Million in Common Shares

Reuters
·
Aug 20

Halozyme Appoints COUR Pharma CEO Dannielle Appelhans to Board

Reuters
·
Aug 19

Halozyme Appoints Dannielle Appelhans to Its Board of Directors

THOMSON REUTERS
·
Aug 19

Sagtec announces commercial launch of HALO AI Food-Serving Robot

TIPRANKS
·
Aug 18

Movement Alert|Halozyme Therapeutics Rises 5.05% in Regular Trading, Continued Momentum After Q2 Earnings Beat and Analyst Upgrades

Market Focus
·
Aug 18

Halozyme Director Bernadette Connaughton Disposes of 1.626 Shares Worth $167.152,8

Reuters
·
Aug 12

What Halozyme Therapeutics (HALO) Guidance Raise Means For Valuation

Simply Wall St.
·
Aug 11

Movement Alert|Halozyme Therapeutics Rises 16.87% in Regular Trading, Q2 Earnings Massively Beat Expectations with Full-Year Guidance Raised

Market Focus
·
Aug 08

Halozyme price target raised to $105 from $93 at Morgan Stanley

TIPRANKS
·
Aug 07

Halozyme Therapeutics is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Aug 07

Halozyme Therapeutics, Inc. : Leerink Partners Raises to Outperform from Market Perform; Raises Target Price to $110 from $83

THOMSON REUTERS
·
Aug 07

Halozyme Therapeutics, Inc. : Wells Fargo Raises Target Price to $95 from $75

THOMSON REUTERS
·
Aug 07

Morgan Stanley Adjusts PT on Halozyme Therapeutics to $105 From $93, Maintains Overweight Rating

MT Newswires Live
·
Aug 07

Movement Alert|Halozyme Therapeutics Rises 5.38% in Pre-Market Trading, Q2 Earnings Massively Beat Expectations with Full-Year Guidance Sharply Raised

Market Focus
·
Aug 07

Movement Alert|Halozyme Therapeutics Overnight Rise 6.08%, Q2 Earnings Significantly Beat Expectations with Full-Year Guidance Raised

Market Focus
·
Aug 07

Analysts Offer Insights on Healthcare Companies: Compass Therapeutics (CMPX) and Halozyme (HALO)

TIPRANKS
·
Aug 07

Stock Track | Halozyme Therapeutics Soars 5.39% in After-Hours Trading on Q2 Earnings Beat and Raised Guidance

Stock Track
·
Aug 07